At present, ADC drugs are mainly used in the field of tumors, so antigenic targets are required to be highly expressed in tumor cells but with low or no expression in normalRead More…
Clinical Results of immunogenicity of Multiple ADC Molecules
Protein drugs have high risks of inducing immunogenicity, which may affect the efficacy or even be life-threatening. Most biotherapies, such as antibody-drug conjugates (ADCs), fusion proteins, and polyethylene glycolization, carry unnatural humanRead More…
Booming 2020 for ADC—Achieved $40 billion Trade
ADC drugs are undoubtedly the focus of many pharmaceutical companies competing for layout in 2020, reaching $40 billion deal in less than a year. AstraZeneca built a partnership with the Daiichi SankyoRead More…
Analysis of the ADCs Drugs Approved by FDA
Antibody-drug conjugate (ADC) has achieved great progress in the past decade. So far, ten ADC drugs have been approved by the FDA, of which five were approved in 2019 and 2020, andRead More…
Design ADC with Creative Biolabs – Episode II
In the last blog, we learned that the main feature of ADC candidate target antigen is that it needs to be highly expressed on the surface of tumor cells and not expressedRead More…
Design ADC with Creative Biolabs-Episode I
As we all known, antibody-drug conjugate (ADC) is a drug obtained by chemical conjuagtion of antibody, linker and cytotoxin. Compared with simple monoclonal antibodies, ADC has better targeting and more efficient killingRead More…
Blockbuster Deal for ADC: Merck Sharp & Dohme and Seattle Genetics Reach a $4.5 Billion Partnership
On September 13, 2020, Gilead announced that it would acquire Immunomedics, whose core product is Trop-2 ADC drug Trodelvy, for more than $20 billion. On September 14, 2020, Merck Sharp & DohmeRead More…
Big Deal: Gilead Acquired Immunomedics for Nearly $20 Billion to Get Hot ADC Drugs
On Sept. 12, the Wall Street Journal reported that Gilead was reaching an acquisition agreement of more than $20 billion with Immunomedics to expand its oncology product pipeline, including trodelvy (sacituzumab govitecan),Read More…
Medical Missile-ADC Drug-Will Take-Off
Recently, AstraZeneca reached a global development and commercialization agreement of up to US $6 billion with the Daiichi Sankyo Company Limited for the development and commercialization of the antibody-drug conjugate (ADC). ThisRead More…
A Noval ADC for DLBCL Get Accelerated Approval
Recently, the United States Food and Drug Administration announced the accelerated approval of the antibody-conjugate drug (ADC) Polivy (polatuzumab vedotin-piiq) for the treatment of refractory adult patients with diffuse large B-cell lymphomaRead More…